Hematology (all articles)
RCT | Hypophosphataemia following ferric derisomaltose vs. ferric carboxymaltose in patients with iron deficiency anemia due to IBD.
16 Dec, 2022 | 13:15h | UTC
Major hemorrhage: past, present and future.
13 Dec, 2022 | 14:05h | UTCMajor haemorrhage: past, present and future – Anaesthesia
Single-arm P1 study | Talquetamab, a T-Cell–redirecting GPRC5D bispecific antibody for multiple myeloma.
12 Dec, 2022 | 12:38h | UTCTalquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Talquetamab, a bifunctional antibody, directs activated T cells to tumor. In this study, up to 70% of the patients with relapsed or refractory myeloma had a response to this agent. https://t.co/OJGHobKG0E pic.twitter.com/53soLSCepA
— NEJM (@NEJM) December 10, 2022
Single-arm P1/2 study | Glofitamab for relapsed or refractory diffuse Large B-Cell Lymphoma.
12 Dec, 2022 | 12:37h | UTCGlofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Glofitamab, a bifunctional antibody, was given to 154 patients with relapsed or refractory DLBCL. Complete response occurred in 39%; most of these responses were ongoing at 12 months. Cytokine release syndrome was common. https://t.co/FWavXlkVXD pic.twitter.com/F4eyYja2E4
— NEJM (@NEJM) December 11, 2022
M-A | Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage.
9 Dec, 2022 | 13:17h | UTC
Commentary on Twitter
Meta-analysis finds mostly successful DOAC reversal with 4F-PCC (77%), andexanet alfa (AA)(75%), and idarucizumab (82%) in patients with ICH. 4F-PCC and AA had comparable success in factor Xa inhibitor reversal, mortality, and thromboembolic outcomes. #OA https://t.co/aieJd9h5jo
— JAMA Network Open (@JAMANetworkOpen) November 4, 2022
Preliminary study suggests that Edoxaban is a safe alternative for preventing thromboembolism in pediatric patients with cardiac disease.
9 Dec, 2022 | 13:07h | UTCEdoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Cohort Study | Cutaneous involvement in catastrophic antiphospholipid syndrome.
8 Dec, 2022 | 12:53h | UTCCutaneous Involvement in Catastrophic Antiphospholipid Syndrome in a Multicenter Cohort of 65 Patients – JAMA Dermatology (free for a limited period)
Commentary on Twitter
In this cohort study, half of patients with catastrophic APS (CAPS) showed cutaneous involvement, with a spectrum of clinical presentations, including distal inflammatory edema. Skin biopsies confirmed diagnosis in all but 1 biopsied patient. https://t.co/lwBL3lyLxT
— JAMA Dermatology (@JAMADerm) December 7, 2022
RCT | Fostamatinib for the treatment of patients with primary immune thrombocytopenia.
7 Dec, 2022 | 14:18h | UTC
Review | AL Amyloidosis for Cardiologists.
6 Dec, 2022 | 13:36h | UTC
RCT | Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis.
2 Dec, 2022 | 14:24h | UTCRivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis – NEJM Evidence
Commentary on Twitter
This #RCT examined the use of rivaroxaban to reduce risk of venous thromboembolism (VTE) in pts with non-cirrhotic chronic portal vein thrombosis (PVT). Daily rivaroxaban reduced incidence of VTE and did not increase major bleeding events. https://t.co/CbenUb8ZWz#LiverTwitter pic.twitter.com/bgN1QS171j
— NEJM Evidence (@NEJMEvidence) November 22, 2022
Joint consensus statement on the vaccination of adult and pediatric hematopoietic stem cell transplant recipients.
30 Nov, 2022 | 13:39h | UTC
Consensus Paper | Hematopoietic cell transplantation in the management of myelodysplastic syndrome.
29 Nov, 2022 | 14:11h | UTC
Cohort Study | Trends and risk factors for venous thromboembolism among hospitalized medical patients.
29 Nov, 2022 | 14:04h | UTC
Commentary on Twitter
1.2% of hospitalized patients developed a hospital-associated venous thromboembolism (HA-VTE), slightly increasing from 2013-2016 (1.1-1.6%). 78% happened after discharge; HA-VTE were linked to higher risk of readmission and death. @KPDOR https://t.co/cB8VhY7k7X #OAResearch
— JAMA Network Open (@JAMANetworkOpen) November 21, 2022
Post-trial follow-up | OS with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma.
25 Nov, 2022 | 12:25h | UTCOriginal Study: Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma – New England Journal of Medicine
RCT | Anticoagulation for 3 months reduces recurrence rates vs. treatment for 6 weeks in patients with isolated distal DVT.
24 Nov, 2022 | 13:34h | UTCNews Release: Extending anti-clotting treatment after distal DVT reduces further clot risk – BMJ Newsroom
SR | Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding.
24 Nov, 2022 | 13:24h | UTC
RCT | Leniolisib for Activated phosphoinositide 3-kinase delta syndrome.
22 Nov, 2022 | 13:12h | UTC
RCT | Zanubrutinib vs. Ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
22 Nov, 2022 | 13:03h | UTC
M-A | Prophylactic platelet transfusions vs. no prophylaxis in hospitalized patients with thrombocytopenia.
21 Nov, 2022 | 13:59h | UTC
RCT | A small study tested Apixaban’s efficacy and safety versus a Vitamin K-antagonist in patients on chronic hemodialysis.
11 Nov, 2022 | 13:52h | UTCRelated Study: Apixaban for Patients with Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial – Circulation
Single-arm P1/2 study | Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma.
11 Nov, 2022 | 13:05h | UTCIberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentaries on Twitter
In a phase I trial of the novel cereblon E3 ligase modulator iberdomide+dexamethasone in pts with RRMM, SAEs occurred in 53%, with one treatment-related death. The ORRs were 32% in the dose-escalation (n=90) & 26% in the dose-expansion (n=107) cohorts: https://t.co/rfRCUfCABb
— NatureRevClinOncol (@NatRevClinOncol) October 14, 2022
NEW research: iberdomide plus dexa was generally safe and showed meaningful clinical activity in heavily pretreated patients with multiple myeloma, including in disease that was refractory to immunomodulatory drugs in this ph 1-2 trial #mmsmhttps://t.co/x1ta31eKtk pic.twitter.com/2URVIoFIAi
— The Lancet Haematology (@TheLancetHaem) October 7, 2022
RCT | Intermediate-dose no better than low-dose LMWH in pregnant and post-partum women with previous thromboembolism.
10 Nov, 2022 | 14:12h | UTCIntermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial – The Lancet (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial https://t.co/9zHeUIda7o
— Saskia Middeldorp (@MiddeldorpS) October 28, 2022
RCT | Prophylactic tranexamic acid did not decrease bleeding in patients with hematologic malignancy.
10 Nov, 2022 | 13:36h | UTCCommentary: Tranexamic Acid (TXA) Prophylaxis in Patients with Hematologic Malignancies – Physician’s Weekly
M-A | DOACs increase the risk of arterial thrombosis vs. Vitamin-K antagonists in antiphospholipid syndrome.
9 Nov, 2022 | 12:28h | UTCDirect Oral Anticoagulants vs Vitamin-K Antagonists in Thrombotic Antiphospholipid Syndrome: Meta-analysis of Randomized Controlled Trials – Journal of the American College of Cardiology (link to abstract – $ for full-text)
RCT | Brentuximab Vedotin with chemotherapy in pediatric high-risk Hodgkin’s Lymphoma.
4 Nov, 2022 | 13:30h | UTCBrentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)